Summary
VXRT trading today lower at $0.4, a decrease of 0.5% from yesterday's close, completing a monthly decrease of -9.55% or $0.04. Over the past 12 months, VXRT stock lost -40.6%.
VXRT pays dividends to its shareholders, with the most recent payment made on Nov 08, 2012. The next estimated payment will be in 8 Nov 2012 on Nov 08, 2012 for a total of $12.188.
The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
Vaxart Inc. has completed 2 stock splits, with the recent split occurring on Feb 14, 2018.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track VXRT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
VXRT Chart
Loading, please wait...
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m.
Globenewswire | 1 week ago
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET.
Globenewswire | 1 week ago
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif.
Globenewswire | 1 week ago
Vaxart Inc. Dividends
 VXRT 9 Nov 2012 Paid | Other | $12.19 Per Share |
Vaxart Inc. Earnings
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
| VXRT 9 Nov 2012 Paid | Other | $12.19 Per Share |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
Vaxart Inc. (VXRT) FAQ
What is the stock price today?
The current price is $0.40.
On which exchange is it traded?
Vaxart Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is VXRT.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 90.26M.
Has Vaxart Inc. ever had a stock split?
Vaxart Inc. had 2 splits and the recent split was on Feb 14, 2018.
Vaxart Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Steven Lo CEO | NASDAQ (CM) Exchange | 92243A200 Cusip |
| US Country | 105 Employees | 14 Feb 2018 Last Dividend | 14 Feb 2018 Last Split | 12 Feb 2018 IPO Date |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Contact Information
Address: 170 Harbor Way
Phone: 650 550 3500
Website: https://vaxart.com
2025 © Marketlog. All Rights Reserved.
